Viosera Therapeutics, Inc.

Using AI to predict and block drug resistance in cancer and bacteria

St. Louis-based Viosera is a pre-clincial drug development company formed by Chris Bulow and Nick Goldner in July 2016 as a platform to study and treat drug resistance diseases such as Methicillin-resistant Staphylococcus aureus (MRSA) and various forms of cancer. By studying and understanding the mechanisms by which diseases mutate to evade treatment, `Viosera identifies continuously susceptibility loops and combines the effective drugs into a combination therapy. VT1, Viosera’s flagship drug for MRSA is an intravenously administered antibiotic therapy comprised of three FDA-approved off-patent antibiotics given at a specific ratio that converts MRSA’s antibiotic resistance mechanisms into weaknesses, restoring susceptibility. The component drugs have a large safety window and are already manufactured at scale, allowing the company to effectively source GMP active pharmaceutical ingredients (APIs) for clinical and commercial development.